Your Heartburn May Not Be Harmless

Take Charge of your health

Don’t ignore the signs. Get the care you need today.

FIND A SPECIALIST

Learn how radiofrequency ablation therapy helped Juan Carlos, a Barrett’s esophagus patient.

WATCH THE VIDEO

A Serious Disease Progression

Understanding heartburn, gastroesophageal reflux disease (GERD), and Barrett's esophagus (BE) is the first step toward getting the right care. Early detection and treatment can reduce your risk of progressing to esophageal adenocarcinoma (EAC).1,2

GET MORE INFORMATION

Get the information you need to take charge of your health. Submit the form below to receive helpful periodic emails with more information and resources.

By checking this box you verify that you have read and agree to these Legal Statements and Privacy Policy. In addition you agree to permit Medtronic to send you materials on its products and services that may interest you. Also, Medtronic may contact you from time to time to collect additional information and inform you about special offers and updates on the Barrx™ RF ablation system or other Barrett's esophagus related health matters. Moreover, you authorize Medtronic to use the personal information you have provided on this form for the purposes stated herein.


If you ever wish to stop receiving email updates, you can unsubscribe at any time.

References: 1. Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12)1209-17.  2. Shaheen NJ, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009, 360:2277-88  3. Vaezi M, Zehrai A, Yuksel E. Testing for refractory gastroesophageal reflux disease. ASGE Leading Edge. 2012;2(2):1-13. American Society Gastroenterology Endoscopy, Pages 1-4.  4. Dymedex Market Development Consulting, GERD Sizing and Segmentation for pH Testing. February 13, 2015.  5. Dymedex Market Development Consulting, Strategic Market Assessment: Barrx-GI, October 30, 2014.  6. SEER Cancer Statistics Factsheets: Esophageal Cancer. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/statfacts/html/esoph.html.  7. Pohl H, Welch G et al. The role of over diagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005;97:142-6.  8. SEER Cancer Statistics Animator, 1975-2012. National Cancer Institute. Bethesda, MD.